Source: Annual Congress 2010 - Experimental pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. C. Weisel, G. Kwapiszewska, C. Kloepping, M. Roth, H. A. Ghofrani, R. T. Schermuly, W. Seeger, F. Grimminger, N. Weissmann (Giessen, Bad Nauheim, Germany). Vascular reverse remodeling in the mouse model of hypoxia-induced pulmonary hypertension. Eur Respir J 2010; 36: Suppl. 54, 1076

Member's Comments

No comment yet.

Related content which might interest you: Targeting TMEM16A to reverse vasoconstriction and remodelling in idiopathic pulmonary arterial hypertension Source: Eur Respir J, 53 (6) 1800965; 10.1183/13993003.00965-2018 Year: 2019 2-Ethoxyestradiol inhibits vascular and cardiac remodeling and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007 Vascular remodelling is reversed following BMPR2 modified endothelial progenitor cell therapy in a MCT-induced PAH rat model Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 2-Methoxyestrone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2008 - Pulmonary vascular biology Year: 2008 VEGF reduces pulmonary hypertension and vascular remodeling in pulmonary fibrosis through reduced endothelial apoptosis Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 Regulation of connexins by hypoxia in rat pulmonary vascular cells in an in vitro model of pulmonary hypertension Source: International Congress 2017 – Experimental PH Year: 2017 In a model of genetic pulmonary hypertension, VIP attenuates pulmonary vascular remodeling and right ventricular hypertrophy Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension Year: 2007 Loss of Bmp9 does not lead to spontaneous pulmonary hypertension, but attenuates vascular remodeling in experimental models Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Involvement of FHL1 in vascular remodelling Source: Annual Congress 2006 - Lung vascular and parenchymal remodeling Year: 2006 Hypoxia-induced pulmonary artery fibroblast proliferation and migration is prevented by ASK1 inhibition in an in vitro cellular model of pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Endothelial NO and its pathophysiologic regulation Source: Annual Congress 2007 - Role of the endothelium in pulmonary function and disease Year: 2007 Pulmonary hypertension: the science behind the disease spectrum Source: Eur Respir Rev 2012; 21: 19-26 Year: 2012 Potential contribution of precursor cells to vascular remodeling in the AdTGF-β1 model of lung fibrosis and pulmonary hypertension Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011 Inflammatory changes in a murine model of monocrotaline-induced pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 365s Year: 2005 Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats Source: Eur Respir J 2011; 37: 1104-1118 Year: 2011 Inhibition of the Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling Year: 2006 Endothelial-derived MIF contributes to pulmonary endothelial cell proliferation in human pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 PDGF promotes pulmonary artery smooth muscle cell proliferation and migration in pulmonary arterial hypertension Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Effects of a novel azaindole-based Rho-kinase inhibitor on hemodynamics and pulmonary vascular remodelling in experimental pulmonary hypertension Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases Year: 2009